SGO Annual Meeting - Sunday/ Monday

Delayed but here are some important tweets from the SGO meeting on Sunday and Monday.


Risk Reducing Salpingectomy and QOL

.@karenluMD presenting important #QOL data regarding risk-reducing salpingectomy in #BRCA mutant #previvors of #OvarianCancer salpingectomy led to decreased cancer worry, low decision regret, and fewer menopausal symptoms #gyncsm #SGOHawaii50 #SGOMtg pic.twitter.com/CFceeOmORX

— Shannon Westin (@ShannonWestin) March 17, 2019

@karenluMD presents important @SU2C #OvarianCancer Dream Team WISP results re delayed oophorectomy vs risk reducing salpingo-oophorectomy in high risk patients. #SGOmtg #gyncsm @ocrahope @NOCC_National pic.twitter.com/76KvvQNwhn

— Annie Ellis (@Stigetta) March 17, 2019

 Phase 1 Levantinib and weekly taxol in recurrent OC

Amazing early results #SGOHawaii50 https://t.co/fHwMds3fNz

— Stephanie Blank (@StephanieVBlank) March 17, 2019

PARP and ARID1A

Representing @VCUMassey at #SGOHawaii50! So much excitement over #PARP - I’m honored to be part of this innovative project! @temkins @emma pic.twitter.com/QUFcuIlkwM

— Stephanie Sullivan (@StephASullivan) March 17, 2019

JAVELIN  - Avelumab+peg liposomal doxorubicin VS peg liposomal doxorubicin

Phase 3 JAVELIN results at #SGOmtg: failed to meet primary endpoint; no overall signif. improvement in PFS or OS w/avelumab+peg liposomal doxorubicin vs. PLD alone in platinum-res/ref epithelial OC, but trend toward improvement in PD-L1+ tumors. #SGOHawaii50 @MDEdgeTweets

— Sharon Worcester (@SW_MedReporter) March 17, 2019

Phase 2 Pembro and Bev

Dr. Zsiros presents P2 results of pembro combo with bev and cyclophosphamide #sgomtg #gyncsm pic.twitter.com/6W5GZ3Gymp

— Annie Ellis (@Stigetta) March 17, 2019

Minorities and clinical trials

This is unacceptable. “Minority patients continue to suffer the greatest consequences.” How can we get more minorities involved in clinical trials?? We need to act on what we know. #SGO50Hawaii #SGOMtg pic.twitter.com/Cs01Yft18H

— Kristin Koerten (@KMKoerten) March 18, 2019

OC Patient Preferences - maintenance therapy

.@LarissaAMeyerMD presents her important work regarding patient preferences for maintenance therapy in #OvarianCancer - patients trust their doctor’s recommendation! #gyncsm #SGOHawaii50 #SGOMtg pic.twitter.com/bleUKGbten

— Shannon Westin (@ShannonWestin) March 18, 2019

CCNE1 and BRD4 Expression and platinum resistance

⁦@riskaMD2014⁩ presenting our work #SGOMTG #SGOHawaii50 #gyncsm. Representing ⁦@KUMedCenter⁩ ⁦@KUcancercenter⁩! pic.twitter.com/uhg9hvx7ii

— DineoKhabeleMD (@DKhabeleMD) March 18, 2019

 Thank you @KMKoerten , @DKhabeleMD, @ShannonWestin, @Stigetta, @SW_MedReporter, @StephASullivan, @StephanieVBlank for posting from the meeting!


Dee
Every Day is a Blessing!